

## **Nomination committee appointed for Cyxone Annual General Meeting 2023**

**Cyxone AB (publ) hereby announces that the members of the nomination committee have been appointed ahead of the 2023 AGM. The nomination committee has been appointed in accordance with the guidelines laid down at the 2022 AGM**

The nomination committee shall consist of four members, one representing each of the three largest shareholders along with the chairman of the board, in accordance with the principles adopted during the annual general meeting held on Monday, May 16, 2022.

The nomination committee consists of:

- Ivar Nordqvist
- Göran Ofsén
- Bert Junno, chairman of the board of Cyxone AB
- Mikael Lindstam, board member of Cyxone AB

The nomination committee is tasked with making proposals for board members and board fees. Furthermore, the nomination committee must submit proposals to the auditor and auditor's fee, chairman of the meeting and, to the extent deemed necessary, changes to the instructions for the nomination committee.

Shareholders who wish to submit proposals to the nomination committee can do so via e-mail to [valberedning@cyxone.com](mailto:valberedning@cyxone.com) or the following address:

To: Valberedningen  
Cyxone AB  
Hyllie Boulevard 34  
215 32 Malmö

The nomination committee's proposal will be presented in the notice to the annual general meeting.

### **Contact**

Carl-Magnus Högerkorp, acting CEO  
Tel: +46 (0)70 781 88 12  
Email: [carl.hogerkorp@cyxone.com](mailto:carl.hogerkorp@cyxone.com)

### **About Cyxone**

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit [www.cyxone.com](http://www.cyxone.com)